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http://dx.doi.org/10.1016/j.ccr.2012.12.008SUMMARYThe LKB1 (also called STK11) tumor suppressor is mutationally inactivated in 20% of non-small cell lung
cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making
LKB1-deficient cells unable to appropriately sense metabolic stress. We tested the therapeutic potential
of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes
therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells. Therapeutic trials in
Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1mutations, but not those
with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in pro-
longed survival. This study suggests phenformin as a cancer metabolism-based therapeutic to selectively
target LKB1-deficient tumors.INTRODUCTION
The gene encoding the serine/threonine kinase LKB1 was identi-
fied originally as the tumor suppressor gene responsible for the
inherited cancer disorder Peutz-Jeghers syndrome (Hemminki
et al., 1998). LKB1 is also the second most commonly mutated
tumor suppressor in sporadic human lung cancer (after TP53),
particularly in multiple subtypes of NSCLC (Sanchez-Cespedes
et al., 2002). LKB1 is mutated in at least 15%–30% of NSCLCs,
but the true frequency might be even higher because of difficul-
ties in detecting inactivating lesions (Ding et al., 2008; Gill et al.,
2011; Ji et al., 2007). Roughly half of the NSCLC tumors with
LKB1mutation also bear activatingKRASmutations, and currentSignificance
Targeted therapeutics are making significant advances in subs
EGFR andALK. More prevalent in NSCLC aremutations in theK
tumor suppressor genes. Currently, there are limited options fo
LKB1-defective cells to metabolic stress and test the therapeu
type 2 diabetes drug, in mouse models of NSCLC. Phenform
survival in Kras;Lkb1 compound mutant mice but not Kras;p53
may find clinical utility to treat NSCLC bearing LKB1 mutation
Cestimates suggest that 7%–10% of all NSCLC are comutated for
KRAS and LKB1 (Ding et al., 2008; The Cancer Genome Atlas).
Studies in genetically engineered mouse models have shown
that simultaneous activation of KrasG12D and biallelic deletion of
Lkb1 in the lung dramatically increases tumor burden andmetas-
tasis (Carretero et al., 2010; Chen et al., 2012; Ji et al., 2007).
Biochemical and genetic analyses in worms, flies, and mice
have shown that LKB1 is the major kinase phosphorylating the
AMP-activated protein kinase (AMPK) under conditions of
energy stress across metazoans (Hardie et al., 2012). AMPK is
a highly conserved energy sensor and modulator of cell growth
and metabolism that is activated under conditions of low intra-
cellular ATP. Activated AMPK regulates cell growth at least inets of NSCLC bearing activated oncogenic targets, such as
RAS oncogene coincident withmutations in the LKB1 or p53
r LKB1mutant tumors. Here, we define the hypersensitivity of
tic use of phenformin, a mitochondrial inhibitor and a former
in as a single agent reduced tumor burden and prolonged
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Phenformin Therapy Targets LKB1-Deficient NSCLCpart through inhibition of mTORC1 signaling achieved through
dual phosphorylation of TSC2 (Inoki et al., 2003) and Raptor
(Gwinn et al., 2008). AMPK is also hypothesized to maintain
energy homeostasis in part by targeting defective mitochondria
for autophagy (Egan et al., 2011) and control of fatty acid metab-
olism (Jeon et al., 2012).
The diabetes therapeutic biguanide compounds metformin
and phenformin have been shown to inhibit complex I of the
mitochondria (Dykens et al., 2008; El-Mir et al., 2000; Owen
et al., 2000), resulting in increases in intracellular AMP and
ADP that bind to the gamma regulatory subunit of AMPK and
trigger LKB1-dependent phosphorylation of AMPK (Hawley
et al., 2010). Consistent with activation of a low energy check-
point, metformin treatment has been found to reduce tumor
growth in xenograft, transgenic, and carcinogen-inducedmouse
cancer models (Algire et al., 2011; Anisimov et al., 2005; Buzzai
et al., 2007; Memmott et al., 2010). Epidemiological studies
revealed that diabetic patients taking metformin show a statisti-
cally significant reduced tumor incidence (Dowling et al., 2012;
Evans et al., 2005). Given the extensive knowledge on the safety
and use of metformin, there is increasing interest in using
metformin as an anticancer agent (Taubes, 2012). Phenformin
is a 50-fold more potent inhibitor of mitochondrial complex I
than metformin (Dykens et al., 2008; Owen et al., 2000). More-
over, uptake of metformin, but not phenformin, into tissue
appears to require the expression of Organic Cation Transporter
1 (OCT1), which is highly expressed in hepatocytes but not
elsewhere (Shu et al., 2007). Consistent with greater potency
and broader tissue bioavailability, phenformin delayed tumor
progression in a Pten+/ spontaneous lymphoma mouse model
to a much greater extent than metformin (Huang et al., 2008).
In most settings metabolic stress induces a cytostatic growth
arrest, dependent in part on AMPK. However, in cells lacking
a functional LKB1 pathway, metabolic stress has been demon-
strated to result in rapid apoptosis as the cells are unable to
sense the energy stress and activate mechanisms to restore
energy homeostasis (Shaw et al., 2004). Similar effects are
seen in autophagy-defective cells that are unable to restore
metabolism under low nutrient conditions (Jin et al., 2007).
Here, we directly examine the hypothesis that LKB1-deficient
lung tumors may be targeted with metabolic drugs.
RESULTS
Phenformin Selectively Induces Apoptosis
in LKB1-Deficient NSCLC Cell Lines
We previously reported that nontransformed murine embryonic
fibroblasts and HeLa cervical carcinoma cells deficient ofFigure 1. Phenformin Selectively Induces Apoptosis in LKB1–/– NSCLC
(A) A549 human NSCLC cells expressing the pBabe vector (A549-pBabe), full-le
with vehicle (DMEM), AICAR (2mM), metformin (20mM), phenformin (2mM), 2DG
indicated antibodies.
(B) A549 isogenic cell lines were treated for 24 hr with vehicle (DMEM), 2 mM phe
antibodies.
(C) Fluorescence-activated cell sorting (FACS) on cells stained with AnnexinV-PE
(D) H460, H157, or A427 cell lines expressing the pBabe vector (pBabe), full-len
with vehicle (DMEM), 2 mM phenformin, or 20 mM metformin. Lysates were imm
in these cell lines listed under each.
See also Figure S1.
CLKB1 exhibit increased apoptosis in response to metabolic
stresses, including glucose deprivation and the AMP mimetic
AICAR (Shaw et al., 2004). However, whether tumor cells
undergo growth arrest or apoptosis following a particular cellular
insult is dependent in part on the full constellation of oncogenic
mutations present in the cell. We sought to determine whether
NSCLC cell lines bearing KRAS mutations and lacking LKB1
would show enhanced rates of apoptosis following metabolic
stress treatments compared to isogenic lines in which wild-
type LKB1 had been restored.
We performed our initial studies using the KRAS mutant and
LKB1-deficient NSCLC cell line A549 and derivatives with retro-
virally introduced stable expression of wild-type LKB1 cDNA
(LKB1WT), a kinase-inactive LKB1 cDNA (LKB1KD), or an empty
vector (pBABE). These cells were treated with a variety of
drugs with established roles in causing metabolic stress: metfor-
min, phenformin, the cell permeable AMP-mimetic AICAR, the
glycolysis inhibitor 2-deoxyglucose, or the thiazolidinedione
compound troglitazone that acts as a mitochondrial inhibitor in
addition to effects on PPARg (Hardie et al., 2012). Immunoblot-
ting for cleaved caspase 3 and cleaved PARP as markers of
apoptosis induction, we observed that, of the agents tested,
only phenformin induced apoptosis in the cells lacking functional
LKB1 (Figure 1A). Although both biguanides lowered ATP
production in A549 cells (Figure S1A available online), phenfor-
min reduced cellular ATP more, consistent with previous studies
(Owen et al., 2000; Dykens et al., 2008). The ATP-lowering effect
of both drugs was modestly blunted when wild-type LKB1 was
present, consistent with the current model that AMPK acts to
restore ATP levels and with previous findings in wild-type and
Lkb1-deficient myocytes (Sakamoto et al., 2005). Consistent
with a greater impact on ATP levels, phenformin but not metfor-
min induced apoptosis in A549 cells lacking functional LKB1 by
multiple measures: cleaved PARP and caspase 3 immunoblot
(Figure 1B), activated caspase 3/7 luminescence assay (Fig-
ure S1B), and flow cytometry measuring AnnexinV and 7AAD
staining (Figure 1C).
As human daily doses of metformin routinely run between
500 and 1,000 mg, and phenformin was given in the range of
50 to 100 mg previously when used clinically, we performed
a direct comparison of metformin to phenformin at ratios of 1:1
and 10:1 in time course experiments in isogenic A549 cell lines.
At early time points (8 or 12 hr) metformin at 2 or 20 mM or phen-
formin at 2 mM similarly induced AMPK signaling as shown by
increased P-AMPK and P-Raptor levels (Figure S1C). However,
only phenformin induced higher levels of cellular stress, trig-
gering induction of P-Ser51 eIF2a and its downstream target
CHOP, and markers of apoptosis at later times (Figures 1B andTumor Cells
ngth LKB1 (A549-LKB1WT), or kinase-dead LKB1 (A549-LKB1KD) were treated
(10mM), or troglitazone (25 mM) for 48 hr. Lysates were immunoblotted with the
nformin, or 20 mM metformin. Lysates were immunoblotted with the indicated
and 7AAD following 48 hr treatment with vehicle or 2 mM phenformin.
gth WT LKB1 (LKB1WT), or kinase-dead LKB1 (LKB1KD) were treated for 24 hr
unoblotted with the indicated antibodies. Cancer gene driver mutations found
ancer Cell 23, 143–158, February 11, 2013 ª2013 Elsevier Inc. 145
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Phenformin Therapy Targets LKB1-Deficient NSCLCS1C). eIF2a phosphorylation and upregulation of CHOP is
observed in response to a diverse set of cellular stresses,
including the unfolded protein response, nutrient deprivation,
and mitochondrial stress (Muaddi et al., 2010; Ye et al., 2010;
Chae et al., 2012). This suggests that although AMPK activation
is a rapid and sensitive sensor of ATP loss, its signal plateaus
and does not continue to increase with greater ATP loss, when
additional stress sensing pathways like eIF2a kinases may be
engaged. Note that LKB1 did not impact P-eIF2a or CHOP levels
(Figures 1B and S1C), indicating that eIF2a signaling is behaving
here as an AMPK-independent pathway.
To examine howwidely the sensitivity of cell lines to apoptosis
by phenformin treatment is dictated by LKB1, we tested a panel
of NSCLC lines that all had KRAS and LKB1 mutations, but each
contained additional unique mutations. Isogenic derivatives of
each cell line expressing wild-type or kinase-dead LKB1 were
established and examined for sensitivity to phenformin or met-
formin. Despite each cell line containing different additional
mutations, their sensitivity to undergo apoptosis following phen-
formin treatment was dictated by the LKB1 genotype in all cases
(Figures 1D and S1B). Protection from phenformin-induced
apoptosis was also observed with LKB1-reconstituted NSCLC
and cervical cell lines H838 and HeLa, respectively, that are defi-
cient for LKB1 but wild-type for KRAS (Figure S1B). Taken alto-
gether, these data indicate that LKB1 dictates the sensitivity of
a variety of cancer cell lines to phenformin-induced metabolic
catastrophe regardless of the other tumor mutations present.
Developing Genetically Engineered Mouse Models of
NSCLC that Can Be Monitored by Bioluminescence
Longitudinally
Though a handful of studies have begun examining metabolic
drugs in xenograft models, of particular concern is that subcuta-
neous placing a mass of tumor cells into an nonvascularized
environment and without appropriate basement membrane
attachment will itself result in severe metabolic stress and
AMPK activation (Jeon et al., 2012; Laderoute et al., 2006),
thus altering the very pathways being tested here for their impact
on therapeutic outcome. To better model LKB1-deficient
tumors, we took advantage of the well-characterized adenoviral
cre-induced NSCLCmodels initiated by a conditionally activated
K-ras oncogene (Lox-Stop-Lox-KrasG12D, hereafter called Kras),
combinedwithmice bearing floxed alleles of p53 or Lkb1 (Farago
et al., 2012). As previously reported (Chen et al., 2012; Ji et al.,
2007), when p53 deficiency or Lkb1 deficiency is combined
with Kras activation, there is a dramatic increase in tumor
burden leading to metastasis and earlier death,10–12 weeks
post-cre administration in both Kras;Lkb1L/L and Kras;p53L/L
mice compared to 25+ weeks in Krasmice. To facilitate noninva-
sive imaging of tumor burden in longitudinal studies on these
mice following therapeutic intervention, we crossed Kras,
Kras;Lkb1L/L, or Kras;p53L/L mice with a ROSA26 lox-stop-lox
luciferase allele (hereafter called Luc) (Safran et al., 2003) to
generate Kras;Luc (Kluc),Kras;Lkb1
L/L;Luc (KLluc), or Kras;p53
L/L;
Luc (KPluc) mice. We bred these genotypes into the FVB back-
ground whose white coat allowed for noninvasive biolumines-
cent luciferase imaging without fur removal (Figures S2A–S2C).
On the FVB genetic background, KLluc and KPluc mice exhibited
comparable extents of tumor burden and similar latency.146 Cancer Cell 23, 143–158, February 11, 2013 ª2013 Elsevier Inc.We demonstrated that the bioluminesence output from the
ROSA26-encoded luciferase was proportional to tumor burden
(see the Supplemental Experimental Procedures). Analyzing
lung tumor progression in Kluc, KLluc, and KPluc mice, we de-
tected bioluminescence as early as 4 weeks in KLluc and KPluc
mice and confirmed the presence of adenomas by hematoxylin
and eosin (H&E) staining (Figures 2A–2D; Figures S2A–S2C). At
6 weeks, tumors in the KLluc and KPluc mice began to change
from adenomatous features to a more malignant tumor pheno-
type typical of carcinomas (Figure 2D). The most common
histologic pattern in both KLluc and KPluc mice were high-grade
invasive papillary adenocarcinoma. Squamous cell and adeno-
squamous carcinomawere commonly observed tumor subtypes
in KLluc mice, as previously noted (Ji et al., 2007). Interestingly,
KLluc mice also displayed severe mucinous bronchiolar-epithe-
lial adenocarcinoma (mBEAC) and bronchial mucinous papillary
lesions, which were rarely seen in Kluc orKPlucmice (Figure S2D).
Of note, LKB1 is frequently mutated in NSCLC patients with
mucinous bronchiolar adenocarcinoma (Osoegawa et al., 2011).
Next, we characterized AMPK and mTORC1 signaling in Kluc,
KLluc, and KPluc lung tumors by immunohistochemical staining
for P-AMPK and P-4E-BP1 (Figure 2E). Notably, the KLluc tumors
contained the highest degree of P-4E-BP1, consistent with
mTORC1 being particularly hyperactive in LKB1-deficient
tumors. Lkb1 deletion in the Kras mutant tumors was also
accompanied by near-complete loss of P-AMPK as seen in
many other tissues previously (Figure 2E).
Phenformin Activates the AMPK Signaling Pathway
in Kluc and KPluc Lung Nodules
To further examine their prospects as anticancer agents, we
compared the bioavailability of metformin and phenformin in
mouse lung tissue. Phenformin is a more lipophilic molecule
compared to metformin (Figure S3A) and, unlike metformin
requiring OCT1 for cell entry (Shu et al., 2007), readily permeates
cells and tissues (Hawley et al., 2010; Huang et al., 2008). We
performed intraperitoneal (i.p.) injections of vehicle, metformin,
or phenformin on wild-type mice and isolated lung tissue at 1,
4, and 8 hr postinjection. Immunoblot analysis showed a weaker
activation of the AMPK signaling pathway by metformin that only
was observed at the 1 hr time point, unlike phenformin, which
showed a robust activation at 4 hr postinjection (Figure 3A).
However, mice bearing lung tumors did not tolerate daily i.p.
injections over multiple weeks, and therefore phenformin was
administered through the drinking water of mice fed ad libitum,
as previously described (Appleyard et al., 2012; Huang et al.,
2008). Quantitative analysis of P-AMPK staining in KPluc lung
tumors from mice treated for 2 weeks showed greater activation
of AMPK with phenformin than metformin (Figures S3B and
S3C). As expected, no induction of P-AMPK was ever seen in
KLluc tumors. Measurement of metformin and phenformin in
blood plasma of mice by mass spectrometry revealed that levels
of both were steady over days when administered via drinking
water (Figure S3D).
Immunoblot analysis of snap-frozen Kluc, KLluc, and KPluc lung
tumor nodules revealed that tumors from Kluc and KPluc mice
treated with phenformin had higher levels of AMPK activation
compared to vehicle treated mice, whereas KLluc lung tumors
showed a lack of AMPK signaling as expected (Figure 3B).
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Figure 2. Time Course of Tumor Progression in Kluc, KLluc, and KPluc Lung Tumor Models
(A–C) Tumor progression in Kluc (A), KLluc (B), and KPluc (C) murine lung tumor measured by H&E staining or bioluminescence (bottom panel) at the indicated time
points. Scale bars (black) = 300 mm. Scale bars (white) = 100 mm. Mice shown are representative of 10–12 mice per genotype.
(D) Detailed analysis of H&E-stained lung tumors from a KLlucmouse (red circled mouse from the bottom of B) at 6 weeks post-AdCre administration. Scale bars
(red) = 1 mm, (black) = 500 mm, and (white) = 100 mm.
(E) Immunohistochemical analysis of representative lung tumors fromKluc,KLluc, and KPlucmice 10 weeks post-AdCre administration. Sections were stained with
H&E or the indicated antibodies. Scale bars (black) = 500 mm. Scale bars (white) = 100 mm.
See also Figure S2.
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Figure 3. Phenformin Treatment Activates AMPK Pathway in K-Ras-Driven Lung Tumors In Vivo
(A) Lung tissue lysates from wild-type FVB mice following i.p. injection of saline (0.9%), metformin (300 mg/kg), or phenformin (150 mg/kg) and immunoblotted
with the indicated antibodies.
(B) Lysates of lung tumor nodules from Kluc,KLluc, and KPlucmice treated with vehicle (water) or phenformin via 5 days ad lib feeding were immunoblotted with the
indicated antibodies.
(C) Representative images of Kluc, KLluc, and KPluc lung tumor sections stained with hematoxylin and eosin (H&E), P-AMPK, or P-4E-BP1. P-AMPK or P-4E-BP1
positively stained cells (in green) and nuclei (in blue). Scale bar = 100 mm.
(D and E) Box plots representing themean P-AMPK (D) or P-4E-BP1 (E) signal fromKluc,KLluc, andKPluc lung tumors treatedwith vehicle or phenformin. n = 6mice
analyzed per treatment group in each genotype (Kluc, KLluc, and KPluc) treatment group.
All data are represented as the mean ± SEM.
See also Figure S3.
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Phenformin Therapy Targets LKB1-Deficient NSCLCNormal lung lysates from wild-type FVB mice given phenformin
ad libitum for 2 weeks showed an increase in AMPK signaling
and lowered mTORC1 signaling, when compared to the vehicle
treated mice (Figure S3E). Phenformin also increased levels of
P-eIF2a and its target BiP/Grp78 in normal lung as well as in
lung tumors (Figures S3E and S3F) (the CHOP antibody afore
used recognized human but not mouse CHOP). There was no
observed difference in IGF-IR/IR or Akt signaling between the
vehicle- or phenformin-treated mice. Analysis of the AMPK acti-
vation in lung tumors by quantitative immunohistochemistry
following phenformin treatment paralleled the results observed
by immunoblotting (Figures 3C and 3D), and phenformin was
observed to modestly reduce the mTORC1 substrate P-4E-
BP1 levels in all genotypes (Figures 3C and 3E).
Lkb1–/– Lung Tumors Reveal Higher Levels of Apoptosis
and Reduced Tumor Burden following Phenformin
Treatment
Having established that phenformin had greater bioavailability
and was capable of more potently inducing energy stress in
tumors than metformin, we next tested phenformin as a single-
agent therapeutic in the Kluc, KLluc, and KPluc mice. Following
tumor induction, we performed bioluminescent imaging (BLI) to
monitor tumor growth and sortedmice into equal groups accord-
ing to their BLI value to normalize the cohorts receiving vehicle or
phenformin (Figures S4A–S4C). We first tested phenformin as
a chemotherapeutic by initiating treatment 6 weeks postadeno-
viral cre delivery for the KPluc and KLluc mice and 9 weeks post-
adenoviral cre delivery in the Kluc mice (Figure S4D) in order to
target aggressively growing tumors transitioning from benign
tomalignant tumors (Figures 2A–2C). After 3 weeks of treatment,
BLI imaging revealed modestly reduced tumor burden in mice of
all genotypes receiving phenformin, but the only statistically
significant decrease was in the KLluc lung tumors (Figures 4A
and 4B).
To better quantify tumor burden in mice, we combined BLI
with quantitative histological analysis. H&E-stained lungs were
imaged with morphometric software to quantify the surface
area composed of tumor as opposed to normal tissue of repre-
sentative cross-sections of each lung lobe for each mouse was
determined (Figures S4E and S4F). Importantly, tumor burden
determined by histological analysis correlated closely with BLI.
KLluc mice showed significant reductions in lung tumor area
(Figures 4C and 4D), while modest reductions in tumor burden
were also seen in both Kluc and KPluc mice. Normalization of
the tumor burden for each tumor genotype, performed by calcu-
lating the ratio of phen:veh tumor mass, showed the largest
decrease in tumor burden for the KLluc mice as compared to
Kluc and KPluc mice (Figure S4G). In addition, we observed no
change in rate of metastasis following phenformin treatment in
any of our therapeutic trials. These results demonstrate phenfor-
min as a single agent selectively attenuates Lkb1-deficient lung
tumor growth in vivo.
We next analyzed apoptosis and tumor proliferation in the lung
tumors by TUNEL and Ki67 staining, respectively. Phenformin
treatment modestly reduced Ki67 index in KLluc tumors but not
Kluc and KPluc tumors (Figures 4E and 4F), and TUNEL staining
revealed that KLluc lung tumors had the highest levels of
apoptotic tumor cells following phenformin (Figures 4E andC4G). Interestingly, KLluc lung tumors also had higher basal levels
of apoptosis compared toKPluc andKluc tumors, perhaps reflect-
ing the prosurvival role of LKB1 in restoring energy homeostasis
under conditions of metabolic stress, which may spontaneously
arise in the context of a tumor.
Phenformin Induced a Significant Increase in Survival
and Therapeutic Response in KLluc Mice following
Long-Term Treatment
Given the response of late-stage KLluc lung tumors to phenfor-
min treatment, we decided to treat earlier stage lung tumors in
KLluc and KPluc mice. To better mimic the human clinical use of
biguanides, we used oral gavage (o.p.) to deliver daily the
maximum tolerated dose of 100 mg/kg phenformin starting at
3 weeks posttumor induction (Figure S5A). As expected, delivery
of phenformin by this method resulted in AMPK pathway activa-
tion in KPluc but not KLluc tumor nodules (Figures S5B and S5C).
Mass spectrometry on phenformin in blood plasma following
o.p. delivery demonstrated a rapid uptake of phenformin
followed by a steady decrease in blood plasma over 24 hr (Fig-
ure S5D). Importantly, these FVB mice are on a chow diet and
nondiabetic, and the dose of phenformin used following 6 weeks
of daily administration did not significantly impact blood plasma
insulin levels, glucose levels, or lead to increased blood lactate
levels as compared to vehicle-treated mice (Figures S5E–S5H).
The loss of LKB1 function in tumors predicts increased glyco-
lytic metabolism and 18F-fluoro-2-deoxyglucose positron emis-
sion tomography (FDG-PET) avidity as shown in gastrointestinal
polyps from Lkb1+/ mice (Shackelford et al., 2009) and
in NSCLC in mice and humans (Chen et al., 2012). Therefore,
we explored the use of FDG-PET as a surrogate endstage
biomarker in combination with microCT (mCT) imaging to longitu-
dinally monitor tumor progression and response in KLluc and
KPluc mice following phenformin treatment. KLluc and KPluc
mice were given baseline FDG-PET and mCT scans, which
were scored by a radiologist blinded to the identities of the
mice. Mice in both groups were determined to be negative for
tumors by both PET and CT scans and were randomly sorted
into treatment groups (Figure 5C).
When phenformin was administered by o.p. for an extended
time, it significantly increased survival in KLluc mice compared
toKPlucmice (Figures 5A and 5B). Phenformin treatment resulted
in delayed tumor progression in KLluc but not KPluc mice as
shown by mCT measurements of lung tumor volume over time
for individual mice in the study (Figures 5C–5E, S5J, and S5K).
At 4 and 6 weeks of treatment, average lung tumor size was
significantly reduced in KLlucmice (Figure 5D). There was a trend
toward smaller tumors in the KPluc mice but did not reach statis-
tical significance (Figure 5E). However, at endstage, there was
the presence of large, advanced solid tumors of the vehicle
and phenformin groups in both KLluc and KPluc tumor genotypes
(Figure S5I). The 18FDG uptake into tumors was quantified by the
standardized uptake value (SUVmax) at 4 and 6 weeks of treat-
ment. The SUVmax for phenformin-treated KLluc lung tumors
was significantly reduced compared to vehicle ones (Figure 5F).
No difference was seen in the SUVmax for the KPluc mice at
these same time points (Figure 5G). These data suggest a thera-
peutic response in KLluc lung tumors following phenformin treat-
ment. However, the SUVmax values in endstage tumors wereancer Cell 23, 143–158, February 11, 2013 ª2013 Elsevier Inc. 149
Figure 4. Phenformin Preferentially Inhibits LKB1-Deficient Lung Tumors In Vivo
(A) Representative ventral view images of bioluminescence from Kluc, KLluc, and KPlucmice. Bioluminescence imaging (BLI) performed on Kluc (veh, n = 11; phen,
n = 12mice), KLluc (veh, n = 10; phen, n = 10mice), and KPluc (veh, n = 7; phen, n = 7mice) following 3 weeks of treatment with vehicle (water) or phenformin via ad
lib feeding.
(B) Average BLI for each treatment group of the Kluc, KLluc, and KPluc mice at 3 weeks treatment.
(C) Representative images of tumor burden inKluc,KLluc, andKPlucmice as shown byH&E-stained lung sections (top panel) or the same images tissue segmented
and pseudocolored with Inform software (bottom panel). Scale bar = 1 mm.
(legend continued on next page)
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suggesting the emergence of phenformin-resistant tumors in
KLluc mice (Figures S5J and S5L).
Histopathological analysis of 6 week o.p. phenformin-treated
lungs revealed that KLluc but not KPluc lung tumors had large
regions of necrosis, which was absent in the vehicle-treated
controls (Figure 6A; Figure S6A). Further analysis of KLluc lung
sections revealed an 8-fold increase in necrotic tumor areas as
shown by the presence of necrotic bodies with ghost cells
(Figures 6B and 6F). Staining of KLluc and KPluc tumors for
cleaved caspase 3 revealed a significant increase in tumor cell
apoptosis in both KLluc and KPluc lung tumors following phenfor-
min (Figures 6C, 6G, S6A, and S6B) but no difference in Ki67
indices in either genotype following phenformin treatment
(Figures 6D, 6H, S6A, and S6C). Elevated P-AMPK levels were
observed in both tumor and lung parenchyma of phenformin-
treatedKPlucmice (Figure S6D), further reflecting that this dosing
regimen was capable of inducing energy stress in these different
lung cell populations. Strikingly, the abundant mucinous bron-
chiolar-epithelial adenocarcinoma (mBEAC), which occluded
much of the upper airways in KLluc mice, showed a 2-fold
decrease in surface area inmice receiving phenformin compared
to the vehicle group (Figures 6E and 6I). Altogether, these results
indicate that phenformin as a single agent induces a tumor
response in both KLluc and KPluc lung tumors with Lkb1-deficient
tumors showing the most robust overall therapeutic response to
phenformin.
Mitochondrial Defects May Sensitize LKB1-Deficient
NSCLC Tumor Cells to Phenformin
To examine the molecular mechanism behind the selective
induction of apoptosis in LKB1-deficient lung cancer cells, we
analyzed signals downstream of its main target AMPK. Recently,
we demonstrated that AMPK phosphorylates and activates the
autophagy kinase ULK1, which is required for mitophagy and
cell survival under starvation conditions (Egan et al., 2011). We
previously observed an accumulation of mitochondria with
defective mitochondrial membrane potential (Dc) in Ampk- and
Ulk1-KO fibroblasts and hepatocytes (Egan et al., 2011), similar
to that observed in Lkb1-KO hematopoetic stem cells (Nakada
et al., 2010), so we examined here whether ULK1 and mitochon-
drial homeostasis might be disrupted in LKB1 mutant NSCLC
cells. A549 cells reconstituted with functional LKB1 showed
AMPK activation and its phosphorylation of endogenous ULK1
onSer555 following phenformin treatment, paralleling phosphor-
ylation of Raptor, another AMPK substrate (Figure 7A). Phenfor-
min treatment also resulted in a decrease in levels of the p62/
Sqstm1 protein only in the wild-type LKB1-reconstituted cells,
indicative of efficient autophagy reliant on LKB1 function (Fig-
ure 7A). Importantly, p62 levels were not reduced by metformin
here, perhaps reflecting the lower level of AMPK signaling from(D) Box plots representing the mean tumor burden following 3 weeks of treatment
from H&E-stained whole lung sections shown in (C) bottom panel.
(E) Representative images of H&E-, Ki67-, or TUNEL-stained Kluc,KLluc, andKPluc
(in blue). Scale bar = 100 mm.
(F and G) Box plots representing the mean Ki67 (F) and TUNEL scores (G) from
significance (p < 0.05) calculated using a nonparametric one-way ANOVA (Tukey
All data are represented as the mean ± SEM. See also Figure S4.
Cmetformin as compared to phenformin. Expression of functional
LKB1 in LKB1-deficient H157 and H838 cells also restored their
P-Ser555 ULK1 signal, indicating this is a general defect in
LKB1-deficient NSCLC cell lines (Figure S7A). As observed
previously in AMPK- and ULK1-defective fibroblasts and hepa-
tocytes, here A549, H157, and H838 NSCLC cells defective for
LKB1 function exhibited increased mitochondrial content as as-
sayed by flow cytometry for mitotracker red staining (Figure 7B
and S7B), suggesting that reconstitution of wild-type LKB1 into
these LKB1-deficient NSCLC cell linesmay actively induce func-
tional mitophagy. A549-pBabe and A549-LKB1KD cells had
impaired Dc, reflecting impaired mitochondrial membrane integ-
rity, as exhibited by the failure of JC-1 dye to accumulate in the
mitochondrial membrane when compared to A549-LKB1WT cells
(red to green ratio of JC-1 staining in Figure 7C). Following treat-
ment with phenformin, LKB1-deficient tumor cells showed
a complete loss of mitochondrial membrane potential, whereas
expression of functional LKB1 fully prevented this loss. In
contrast, treatment with the mitochondrial uncoupler CCCP
induced loss of Dc in all cell lines, though LKB1-reconstituted
cells still retained the most mitochondrial membrane potential
(Figure 7C). As one measure of functionality of the mitochondria
in these cell lines, we examined oxygen consumption as a direct
measurement of mitochondrial respiration. Consistent with
mitochondrial defects, A549-pBabe and A549-LKB1KD cells
had a lower basal rate of oxygen consumption rate (OCR) than
the A549WT cells (Figures 7D and S7C). Treatment of these cells
with either phenformin or rotenone resulted in inhibition of mito-
chondrial respiration as shown by an acute drop OCR in levels
(Figures S7C and S7D). OCR levels tracked inversely with mito-
tracker red staining here, consistent with the idea that the
accumulated mitochondria in the LKB1-deficient cells are respi-
ration defective.
Mitochondrial Complex I inhibition has been reported to
induce reactive oxygen species (ROS) similar to that seen with
Complex III inhibition (Hirst et al., 2008; Kushnareva et al.,
2002). Thus, we next examined the release of mitochondrial
reactive oxygen species (mtROS) following the treatment with
phenformin, metformin, or the complex III inhibitor antimycin A
and found that phenformin was a more potent inducer of mtROS
than metformin (Figure S7E). Staining of A549-pBabe and A549-
LKB1KD cells showed modest elevations in mtROS compared to
A549-LKB1WT cells, both basally and following phenformin treat-
ment (Figure 7E). To examine whether the doses of phenformin
used in our therapeutic study were effective enough to induce
LKB1-dependent effects on mitophagy, we performed western
blot analysis of lung tumor nodules from mice with and without
phenformin treatment for 5 days and discovered reduced phos-
phorylation of ULK1 and an accumulation of themitophagy regu-
lator Parkin in KLluc but not Kluc, or KPluc lung tumors (Figure 7F).
These results suggest defects of the AMPK-ULK1 signaling. Tumor burden was calculated by averaging the red pseudocolored tumor area
lung tumor sections. Ki67 or TUNEL positively stained cells (in green) and nuclei
Kluc, KLluc, and KPluc mice treated with vehicle or phenformin. (*) Statistical
test).
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Figure 5. Phenformin Significantly Increased Overall Survival and Slowed Tumor Progression in KLluc Mice Shown by
18FDG-PET and mCT
Imaging
(A and B) Kaplan-Meier survival curves for KLlucmice (A) or KPlucmice (B) treated with vehicle (n = 5) or phenformin (n = 5) for each tumor genotype, respectively,
with a **p = 0.008 for KLluc mice determined by Wilcoxon logrank test.
(legend continued on next page)
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Figure 6. Phenformin Induces a Significant
Therapeutic Response inKLluc Lung Tumors
(A) Hematoxylin and eosin (H&E)-stained whole
lung sections of KLluc mice treated with vehicle
(saline) or phenformin, scale bar = 4 mm.
(B–E) Representative images of lung tumors from
KLluc mice treated with vehicle (saline) or phen-
formin. (B) Tumor necrosis, scale bar = 50 mm. (C)
Activated caspase 3, scale bar = 50 mm. Inset
represents magnification of caspase-3-stained
cells, scale bar = 25 mm. (D) Ki67 stain, scale bar =
50 mm. Inset represents magnification of Ki67-
stained cells, scale bar = 25 mm. (E) Mixture of
bronchiolar-epithelial adenocarcinoma (BEAC)
and mucinous bronchiolar-epithelial adenocarci-
noma (mBEAC) shown with arrow, scale bar =
200 mm. Inset represents magnification of mBEAC
cells, scale bar = 50 mm.
(F) Mean percentage of necrotic tumor area
in vehicle- and phenformin-treated KLluc mice.
**p = 0.002.
(G) Mean percentage of tumor cell apoptosis
from vehicle- and phenformin-treated KLluc mice.
***p < 0.0001.
(H) Ki67 index for vehicle- and phenformin-treated
KLluc mice.
(I) Total BEAC and mBEAC tumor area (mm2) in
vehicle- and-phenformin treated KLluc mice. **p <
0.006. n = 5 KLluc mice per treatment group
(vehicle or phenformin). Statistical analysis per-
formed using an unpaired Student’s t test.
All data are represented as the mean ± SEM. See
also Figure S6.
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ure 7G), which may help sensitize these tumors to the effects
of phenformin on mitochondrial integrity.
DISCUSSION
In this study we have found that the diabetes drug phenformin
shows selective and significant antitumor activity in genetically
engineered mouse models of lung cancer bearing LKB1 muta-
tions. Molecular targeted therapeutics hold great promise for
the future of cancer treatment, but for the 15%–30% of NSCLC
bearing inactivating mutations in LKB1, there has been little in
the way of targeted agents to date. As loss of LKB1 results in(C) Representative images of micro-FDG-PET and CT scans of lungs from KLluc and KPluc mice at baseline (
with vehicle or phenformin. Heart is labeled (H), and tumors are labeled with arrows (white or blue).
(D and E) Mean tumor volume measured by micro-CT at 4 and 6 weeks treatment for KLluc (D) and KPluc (E)
determined by Wilcoxon rank-sum test.
(F and G) Mean FDG-PET SUVmaxmeasured at 4 and 6 weeks treatment for KLluc (F) and KPlucmice (F), resp
Wilcoxon rank-sum test. n = 5 mice per treatment group of each genotype.
All data are represented as the mean ± SEM. See also Figure S5.
Cancer Cell 23, 143–158,hyperactivation of mTORC1 in addition
to other progrowth pathways (Shackel-
ford and Shaw, 2009), initial interest
has been in rapamycin analogs or other
mTOR inhibitors. However, rapamycin
treatment of an autochthonous lungtumor model with Kras and Lkb1 mutations similar to the one
used here showed a minimal therapeutic effect (Liang et al.,
2010), perhaps because of the multitude of pathways deregu-
lated from LKB1 deficiency that can still fuel tumorigenesis
even when mTORC1 is suppressed. Hyperactivation of Src
family kinases was also discovered as a biochemical marker
and potential therapeutic target in Lkb1-deficient lung tumors
(Carretero et al., 2010). Combination of the Src inhibitor dasatinib
with PI3K andMEK inhibitors in similar mouse lung tumormodels
showed a synergistic tumor response, though dasatinib as
a single agent displayed a minimal effect (Carretero et al.,
2010). The fact that phenformin induces therapeutic response
as a single agent taken together with the success of dasatinibpretreatment) or following 4 and 6 weeks treatment
mice, respectively. ***p = 0.0009 for KLluc mice as
ectively. **p = 0.005 for KLlucmice as determined by
February 11, 2013 ª2013 Elsevier Inc. 153
Figure 7. Mitochondrial Defects in LKB1–/– NSCLC Confer Sensitivity to Phenformin
(A) Lysates from A549-pBabe, A549-LKB1WT, and A549-LKB1KD cells were treated with vehicle (DMEM), phenformin (2 mM), or metformin (20 mM) for 4 hr and
immunoblotted with the indicated antibodies.
(B) FACS analysis of cells from (A) stained with Mitotracker Red.
(C) Cells from (A) stained with JC-1 dye following 4 hr of treatment with vehicle (DMEM), phenformin (2 mM), metformin (20mM), or CCCP (100 mM). Mitochondrial
membrane potential (Dc, red/green ratios) were measured by emission of red and green fluorescence using FACS.
(D) Oxygen consumption rate (OCR) of cells from (A).
(E) Cells from (A) were stained with MitoSOX Red following 16 hr of treatment with vehicle (DMEM) or phenformin (2 mM) and analyzed by FACS.
(F) Lung tumor lysates from Kluc,KLluc, and KPlucmice treated 5 days with vehicle or phenformin ad lib feeding were immunoblotted with the indicated antibodies.
(G) Model illustrating mitochondrial defects and phenformin induced cell death in LKB1/-deficient tumor cells.
All data are represented as the mean ± SEM. See also Figure S7.
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greater success in defined combinations, which will be a focus
for future investigations. Of relevance, a recent study treating
the same three NSCLC models used here with a combination
of standard-of-care docetaxel with MEK inhibitors revealed
that Kras; Lkb1 mutant tumors were selectively resistant to that
combination, unlike Kras alone or Kras; p53 mutant tumors
(Chen et al., 2012). It is in the context of this body of work that
selective sensitivity of Kras; Lkb1 tumors to phenformin as
a single agent in aggressive autochthonous models of lung
cancer is so notable.
We have been interested in whether one could utilize meta-
bolic stress-inducing compounds as anticancer agents for
LKB1 mutant tumors in their autochthonous setting in the intact
organism ever since we observed that LKB1-deficient cells were
sensitive to apoptosis induced by metabolic stress in culture
(Shaw et al., 2004). We focused our attention on the biguanide
family of antidiabetes therapeutics for their ability to reduce intra-
cellular ATP levels as a result of mitochondrial complex I inhibi-
tion. The absence of LKB1 signaling to AMPK means such cells
will go for an extended time without activation of this sensor to
restore ATP levels. We expect that mitochondrial damage and
ATP loss also activate AMPK-independent stress sensing path-
ways, as we demonstrate here withmultiple markers of the eIF2a
signaling pathway. These findings are consistent with previous
reports of AMPK-independent effects of biguanides (Foretz
et al., 2010; Kalender et al., 2010). Our results are also consistent
with recent studies demonstrating that AMPK mediates cell
survival following metabolic stress not only through effects on
ATP restoration but also by restoring NADPH levels, which are
needed to neutralize ROS that arise during these stresses
(Jeon et al., 2012). Inhibition of mitochondria complex I has
been shown to cause ROS induction (Hirst et al., 2008; Kushnar-
eva et al., 2002), so the fact that phenformin is a potent complex I
inhibitor may underlie its ROS generation, which LKB1-deficient
cells are genetically incapable of neutralizing efficiently. Future
studies will be needed to fully assess the contribution of ROS
in the LKB1-sensitive apoptosis following phenformin.
The biguanide metformin is the most widely used type 2 dia-
betes therapeutic worldwide and more recently has become
used in treating other insulin-resistant conditions, including
polycystic ovary syndrome (PCOS) (Motta, 2008). Metformin
garnered considerable attention as a potential anticancer agent
once the connection between LKB1 and AMPK was discovered
(Birsoy et al., 2012; Taubes, 2012). As AMPK activation can be
growth suppressive, diabetics taking these agents daily for
decades might have a lowered incidence of cancer because of
chronic effects from AMPK-mediated suppression of mTORC1
and other progrowth pathways, depending on how effective
and sustained the clinical doses of metformin are at activating
AMPK in different tissues. In addition, a non-cell-autonomous
mechanism for metformin’s antitumor effects may be its ability
to lower circulating blood glucose and insulin levels, which
also contribute to cancer risk and incidence in some contexts
(Pollak, 2010). A number of epidemiological studies have found
that diabetics taking metformin exhibit lowered risk of overall
cancer compared to those taking other forms of diabetes medi-
cation (Dowling et al., 2012; Pollak, 2012). Given these observa-
tions, over 50 different clinical trials investigating the use ofCmetformin in oncology are currently underway (http://www.
clinicaltrials.gov). Whether phenformin would yield similar broad
anticancer results, given that it also effectively lowers blood
glucose and also more potently activates AMPK across
a wide-variety of tissues, remains to be investigated. As phenfor-
min has a 50-fold greater potency than metformin for mitochon-
drial complex I inhibition (Owen et al., 2000; Dykens et al., 2008),
part of its therapeutic success in cancer models when compared
to metformin may be due to the fact that at maximal tolerated
doses in rodents and clinically utilized doses in humans, one
achieves greater ATP loss and ROS induction with phenformin.
However, another distinction between these two biguanides is
a greater tissue bioavailability for phenformin, which may be
due to the apparent reliance of metformin on a tissue-restricted
cell-surface transporter, Oct1, to efficiently cross the plasma
membrane, unlike the more lipophilic phenformin (Hawley
et al., 2010). Phenformin was removed from clinical use for
type 2 diabetes because of incidence of fatalities from lactic
acidosis (Crofford, 1995; Owen et al., 2000), reported in 64 cases
per 100,000 patients per year, with patients bearing compro-
mised kidney function at greatest risk. However, phenformin or
another biguanide analog may still find utility as anticancer
agents as the dosing and shorter duration in cancer therapy
would be quite different from its prior clinical use for diabetes.
Patients could also be prescreened for kidney function and other
biomarkers to reduce any risk of lactic acidosis. Based on our
findings here and previous studies of metformin, it seems most
likely that phenformin might have potential use for early-stage
lung tumors or as an adjuvant therapy following resection of
early-stage NSCLC tumors. Although phenformin is unlikely to
be suitable as a single-agent therapy in advanced-stage
disease, it may synergize with other modalities, which warrants
future investigation. A critical need for future clinical studies
will be developing biomarkers of metformin and phenformin
action in human tissues using clinically achievable doses
(Pollak, 2010). Our identification of phospho-Ser51 eIF2a and
its targets CHOP and BiP/Grp78 as AMPK-independent markers
of phenformin-induced stress may prove valuable for such
studies.
Whether LKB1 deficiency confers sensitivity toward other
agents that perturb ATP production via effects on mitochondria,
glycolysis, or glutaminolysis also remains an interesting area
for future targeted therapeutic development. Given the large
percentage of sporadic lung, cervical, and endometrial cancers
bearing LKB1 mutations, identifying agents selectively targeting
LKB1mutant tumors is a critical goal and one that seems partic-
ularly amenable to drugs targeting tumor metabolism.EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Antibodies from Cell Signaling Technologies (Danvers, MA, USA) used for
immunoblots were diluted 1:1,000 and included LKB1 (D60C5) (#3047), phos-
pho-AMPK Thr172 (#2531), total AMPK a1/2 (#2532), phospho-Raptor Ser792
(#2083), total Raptor (#2280), phospho-ULK1 (ser555) (#5869), eIF4E (#9742),
phospho-eIF2a (ser51) (#3398), total eIF2a (#9722), cleaved caspase 3
(#9664), PARP (#9542), cleaved PARP (Asp214) (#5625), cleaved PARP
mouse-specific (Asp214) (#9544), phospho-S6 (ser255/236) (#4858), S6
(#2217), phospho-4E-BP1 (thr37/46) (#2855), 4E-BP1 (#9644), phospho-IGF-
IR/IR (#3024), IGF-IR/IR (#3027), phospho-AKT (ser473) (#4060), AKTancer Cell 23, 143–158, February 11, 2013 ª2013 Elsevier Inc. 155
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Phenformin Therapy Targets LKB1-Deficient NSCLC(#9272), CHOP (#5554), and BiP/GRP78 (#3177). Total ULK1 (A7481 WB
1:1,000) and anti-actin (A5441WB1:5000) were purchased fromSigma-Aldrich
(St. Louis, MO, USA). The p53 (CM5) antibody was obtained from Vector Labs
(Burlingame, CA, USA; VP-P956 WB 1:1,000). The p62 antibody was obtained
from Progen (Heidelberg, Germany; #GP62-C). AICAR was obtained from
Toronto Research Chemicals (North York, Ontario, Canada). Phenformin,
Metformin, and 2-deoxyglucose (2DG) and Antimycin A (cat. no. A8674);
were purchased from Sigma-Aldrich. CCCP was obtained from the Molecular
Probes JC-1 dye kit (Carlsbad, CA, USA; cat no. M34152).
Cell Culture
Cells were incubated at 37C and maintained at 5% CO2. A549, H460, A427,
H838, and HeLa cell lines were obtained from ATCC, and H157 cells were
a kind gift from Dr. John Minna. Cells were grown in Dulbecco’s modified
Eagle’smedium (DMEM) or RPMI 1640medium (GIBCO) plus 10% fetal bovine
serum (Hyclone, Logan, UT, USA) and penicillin and streptomycin. Retroviral
gene expression was performed as described previously (Gwinn et al.,
2008). Briefly, for retroviral infection, the pBabe, pBabe-FLAG-LKB1, and
pBabe-FLAG-LKB1-KD (Addgene #’s 1764, 8592, and 8593) constructs
were transfected along with the ampho packaging plasmid into growing
HEK293T cells. Viral supernatants were collected 48 hr after transfection,
spun for 5 min at 3,000 rpm, and filtered, and target cells were infected in
the presence of polybrene. Twenty-four hours later, cells were selected with
puromycin. Cells were plated at a density of 1 3 105 per well in 6-well dishes
and grown for 18 hr before treatment.
Mouse Therapeutic Trials
Lox-Stop-Lox KrasG12D were obtained from Tyler Jacks at Massachusetts
Institute of Technology (Jackson et al., 2005) and p53lox/lox mice from the
Mouse Models of Human Cancers Consortium (Jonkers et al., 2001).
Lkb1lox/lox mice are as previously reported (Shaw et al., 2005). Rosa26-Lox-
Stop-Lox-Luc mice were obtained from Jackson Laboratories (Bar Harbor,
ME, USA) courtesy of Bill Kaelin (Safran et al., 2003). Mice were inbred on
an FVB background. Lung tumors were induced by intranasal inhalation of
5 3 106 plaque forming units adeno-Cre (purchased from University of Iowa
adenoviral core) as previously described (Jackson et al., 2005). Mice that dis-
played with clinical signs of disease, such as labored breathing or severe
weight loss, were euthanized and necropsied. The mean tumor latencies we
observed were comparable to previous studies with the exception of KPluc
mice, which developed large, aggressive lung tumors with the same latency
of KLluc mice (Jackson et al., 2005; Ji et al., 2007). In the experiments in Fig-
ure 4, mice were administered with vehicle (water), metformin, or phenformin
(Toronto Research Corporation, Ontario, Canada) ad lib through their drinking
water, and their daily intake of fluids were monitored. Fresh metformin
(1.8 mg/ml) or phenformin (1.8 mg/ml) was administered every other day.
Long-term treatments consisted of 3 weeks treatment (schematic in Fig-
ure S4D), and acute treatments lasted 5 days. For the intraperitoneal injections
in Figure 4A, mice were given one injection of saline (0.9%), metformin
(300 mg/kg), or phenformin (150 mg/kg) and euthanized at 1, 4, and 8 hr post-
injection, and lung tissue was isolated. In the therapeutic trials in Figures 5
and 6 (schematized in Figure S5A), mice were administered phenformin
(100 mg/kg/day) by o.p. once daily 6 days/week beginning at 3 weeks postde-
livery of adenovirus expressing Cre. All experimental procedures performed on
mice were approved by the Salk Institute and University of California at Los
Angeles Institutional Animal Care and Use Committees.
Statistical Analysis Methods
Means were compared and p values determined by parametric or nonpara-
metric ANOVA, and statistical test details and significance at p < 0.05 are
indicated in the text and figure legends. Survival curves were computed using
the Kaplan-Meier method. All statistical calculations were carried out using
GraphPad Prism 5 software (San Diego, CA) or SAS 9.3 (SAS, Cary, NC). For
analysis of SUVmax and tumor volume from FDG-PET and mCT imaging,
comparisonsweremade between vehicle (V) versus Phenformin (P) treatments
at week 7 and week 9. Values that were below the level of detection, referred
to as left-censored observations, were coded with ‘‘zero’’, although the
actual value may be above zero but is usually lower than the lowest observed
value.156 Cancer Cell 23, 143–158, February 11, 2013 ª2013 Elsevier Inc.SUPPLEMENTAL INFORMATION
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